These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 25322328)

  • 1. Switching drugs midstream for patients with chronic myeloid leukemia.
    DeAngelo DJ
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):466-8. PubMed ID: 25322328
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
    Koca E; Sevimli F; Cetiner D; Haznedaroglu IC; Sayinalp N; Büyükasik Y; Goker H; Ozcebe O
    Am J Hematol; 2007 Apr; 82(4):333. PubMed ID: 17094091
    [No Abstract]   [Full Text] [Related]  

  • 3. Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.
    Valent P
    Lancet Oncol; 2010 Nov; 11(11):1010-1. PubMed ID: 20965784
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
    Hehlmann R; Lauseker M; Jung-Munkwitz S; Leitner A; Müller MC; Pletsch N; Proetel U; Haferlach C; Schlegelberger B; Balleisen L; Hänel M; Pfirrmann M; Krause SW; Nerl C; Pralle H; Gratwohl A; Hossfeld DK; Hasford J; Hochhaus A; Saussele S
    J Clin Oncol; 2011 Apr; 29(12):1634-42. PubMed ID: 21422420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloid leukemia: room for improvement?
    Baccarani M; Pane F; Rosti G; Russo D; Saglio G
    Haematologica; 2017 Jul; 102(7):1131-1133. PubMed ID: 28655808
    [No Abstract]   [Full Text] [Related]  

  • 6. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
    Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
    Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent advance on chemotherapy of leukemia].
    Nakamura T; Ueda T
    Nihon Naika Gakkai Zasshi; 1994 Sep; 83(9):1531-7. PubMed ID: 7798745
    [No Abstract]   [Full Text] [Related]  

  • 8. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib.
    Jentsch-Ullrich K; Pelz AF; Braun H; Koenigsmann M; Mohren M; Wieacker P; Franke A
    Haematologica; 2004 May; 89(5):ECR15. PubMed ID: 15136244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic myeloid leukemia].
    Hochhaus A
    Dtsch Med Wochenschr; 2011 Oct; 136(40):2007-10. PubMed ID: 21960328
    [No Abstract]   [Full Text] [Related]  

  • 10. Current use of imatinib in the treatment of chronic myeloid leukemia.
    O'Dwyer M
    Haematologica; 2003 Mar; 88(3):241-4. PubMed ID: 12651257
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chronic myelocytic leukemia in children].
    Poliakov VE
    Feldsher Akush; 1991 Nov; 56(11):23-9. PubMed ID: 1807975
    [No Abstract]   [Full Text] [Related]  

  • 12. When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?
    Mahon FX
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):101-103. PubMed ID: 30845112
    [No Abstract]   [Full Text] [Related]  

  • 13. Ph-positive acute lymphoblastic leukemia after long-term remission of Ph-positive acute myeloid leukemia.
    Nishida H; Yoshimizu N; Ueno H; Fujita A; Kato T; Park JW; Yano T; Tobinai K; Ikeda Y
    Leuk Res; 2007 Mar; 31(3):417-8. PubMed ID: 16730062
    [No Abstract]   [Full Text] [Related]  

  • 14. [ATRA (all-trans retinoic acid) in chronic myeloid leukemia?].
    Rák K
    Orv Hetil; 2002 Jun; 143(23):1449-50; author reply 1450. PubMed ID: 12132331
    [No Abstract]   [Full Text] [Related]  

  • 15. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
    Hanfstein B; Müller MC; Hehlmann R; Erben P; Lauseker M; Fabarius A; Schnittger S; Haferlach C; Göhring G; Proetel U; Kolb HJ; Krause SW; Hofmann WK; Schubert J; Einsele H; Dengler J; Hänel M; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Branford S; Hughes TP; Spiekermann K; Baerlocher GM; Pfirrmann M; Hasford J; Saußele S; Hochhaus A; ;
    Leukemia; 2012 Sep; 26(9):2096-102. PubMed ID: 22446502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel combination treatments targeting chronic myeloid leukemia stem cells.
    Al Baghdadi T; Abonour R; Boswell HS
    Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):94-105. PubMed ID: 22178144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era.
    Breccia M; Alimena G
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):135-43. PubMed ID: 20685131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
    Lau A; Seiter K
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
    Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
    Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.